Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 9 Pancreatic Neoplasms 6 Ovarian Neoplasms 5 Sarcoma 4 Neuroblastoma 4 Liver Neoplasms 4 Wilms Tumor 3 Somatostatinoma 3 Rectal Neoplasms 3 Osteosarcoma 3 Neuroendocrine Tumors 3 Neuroectodermal Tumors, Primitive, Peripheral 3 Neoplasms 3 Medulloblastoma 3 Gastrointestinal Stromal Tumors 3 Esophageal Neoplasms 3 Astrocytoma 3 Zollinger-Ellison Syndrome 2 Vipoma 2 Testicular Neoplasms 2 Teratoma 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Pheochromocytoma 2 Ovarian Germ Cell Cancer 2 Optic Nerve Glioma 2 Oligodendroglioma 2 Neoplasm Metastasis 2 Melanoma 2

Interventions

Gemcitabine 95 Cisplatin 72 Capecitabine 39 Oxaliplatin 38 durvalumab 29 Fluorouracil 27 pembrolizumab 26 Leucovorin 23 S 1 (combination) 19 Nivolumab 14 Irinotecan 14 lenvatinib 13 Bevacizumab 13 tremelimumab 10 130-nm albumin-bound paclitaxel 9 apatinib 8 Trastuzumab 7 Injections 7 Immune Checkpoint Inhibitors 7 Docetaxel 7 Albumin-Bound Paclitaxel 7 Paclitaxel 6 Drug Therapy 6 titanium silicide 5 surufatinib 5 irinotecan sucrosofate 5 gemcitabine-oxaliplatin regimen 5 envafolimab 5 camrelizumab 5 atezolizumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × Temozolomide × Gastrointestinal × Clear all

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡